These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 30392867)
1. Another Therapeutic Role for Intravesical Botulinum Toxin: Patients with Long-stay Catheters and Refractory Bladder Pain and Catheter Bypass Leakage. Young MJ; Osman NI; Phillips L; Mangera A; Reid SV; Inman RD; Chapple CR Eur Urol Focus; 2020 Mar; 6(2):339-343. PubMed ID: 30392867 [TBL] [Abstract][Full Text] [Related]
2. British Association of Urological Surgeons (BAUS) and Nurses (BAUN) consensus document: management of the complications of long-term indwelling catheters. Reid S; Brocksom J; Hamid R; Ali A; Thiruchelvam N; Sahai A; Harding C; Biers S; Belal M; Barrett R; Taylor J; Parkinson R BJU Int; 2021 Dec; 128(6):667-677. PubMed ID: 33811741 [TBL] [Abstract][Full Text] [Related]
3. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724 [TBL] [Abstract][Full Text] [Related]
4. Long-term bladder drainage: Suprapubic catheter versus other methods: a scoping review. Hunter KF; Bharmal A; Moore KN Neurourol Urodyn; 2013 Sep; 32(7):944-51. PubMed ID: 23192860 [TBL] [Abstract][Full Text] [Related]
5. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report. Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168 [TBL] [Abstract][Full Text] [Related]
6. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Kuo HC Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645 [TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin injections for adults with overactive bladder syndrome. Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Discontinuation of Botulinum Toxin A Intradetrusor Injections for Neurogenic Detrusor Overactivity: A Multicenter Study. Baron M; Peyronnet B; Aublé A; Hascoet J; Castel-Lacanal E; Miget G; Le Doze S; Prudhomme T; Manunta A; Cornu JN; Gamé X J Urol; 2019 Apr; 201(4):769-776. PubMed ID: 30359679 [TBL] [Abstract][Full Text] [Related]
9. Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration. Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM Urology; 2020 Aug; 142():190-194. PubMed ID: 32437774 [TBL] [Abstract][Full Text] [Related]
10. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial. Pinto RA; Costa D; Morgado A; Pereira P; Charrua A; Silva J; Cruz F J Urol; 2018 Apr; 199(4):998-1003. PubMed ID: 29031769 [TBL] [Abstract][Full Text] [Related]
11. New therapeutic options for refractory neurogenic detrusor overactivity. Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033 [TBL] [Abstract][Full Text] [Related]
12. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639 [TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin injections for adults with overactive bladder syndrome. Duthie J; Wilson DI; Herbison GP; Wilson D Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). Mohee A; Khan A; Harris N; Eardley I BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569 [TBL] [Abstract][Full Text] [Related]
15. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children. Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study. Koh C; Melling CV; Jennings C; Lewis M; Goyal A J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328 [TBL] [Abstract][Full Text] [Related]
17. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Petit H; Wiart L; Gaujard E; Le Breton F; Ferrière JM; Lagueny A; Joseph PA; Barat M Spinal Cord; 1998 Feb; 36(2):91-4. PubMed ID: 9494997 [TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796 [TBL] [Abstract][Full Text] [Related]
19. Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-term Follow-up. Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM Urology; 2018 Apr; 114():167-174. PubMed ID: 29229221 [TBL] [Abstract][Full Text] [Related]